A Single-Center, Randomized, Double-Blind, Placebo-Controlled Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Dose of TAK-792 in the Healthy Japanese and Adult

Trial Profile

A Single-Center, Randomized, Double-Blind, Placebo-Controlled Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Dose of TAK-792 in the Healthy Japanese and Adult

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Nov 2016

At a glance

  • Drugs TAK 792 (Primary)
  • Indications Unspecified
  • Focus Adverse reactions
  • Sponsors Takeda
  • Most Recent Events

    • 24 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 26 Jan 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 24 Nov 2015 Protocol has been amended in treatment table in change of TAK-792 dose from 900 mg to 1250 mg.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top